These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
446 related articles for article (PubMed ID: 28841827)
21. Visual and Anatomic Outcomes in Patients with Diabetic Macular Edema with Limited Initial Anatomic Response to Ranibizumab in RIDE and RISE. Pieramici DJ; Wang PW; Ding B; Gune S Ophthalmology; 2016 Jun; 123(6):1345-50. PubMed ID: 26992841 [TBL] [Abstract][Full Text] [Related]
22. Efficacy/safety of ranibizumab monotherapy or with laser versus laser monotherapy in DME. Berger A; Sheidow T; Cruess AF; Arbour JD; Courseau AS; de Takacsy F Can J Ophthalmol; 2015 Jun; 50(3):209-16. PubMed ID: 26040221 [TBL] [Abstract][Full Text] [Related]
24. Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment: 18-Month, Multicenter, Phase IIIB RELIGHT Study. Pearce I; Banerjee S; Burton BJ; Chakravarthy U; Downey L; Gale RP; Gibson J; Pagliarini S; Patel J; Sivaprasad S; Andrews C; Brittain C; Warburton J; Ophthalmology; 2015 Sep; 122(9):1811-9. PubMed ID: 26150052 [TBL] [Abstract][Full Text] [Related]
25. Comparison of intravitreal ranibizumab and aflibercept for the treatment of diabetic macular edema: a real-world study. Isik P; Sizmaz S; Esen E; Uysal A; Demircan N Int Ophthalmol; 2023 Nov; 43(11):4171-4180. PubMed ID: 37505290 [TBL] [Abstract][Full Text] [Related]
26. Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study. Liu K; Wang H; He W; Ye J; Song Y; Wang Y; Liu X; Wu Z; Chen S; Fan K; Liu Y; Zhang F; Li Z; Liu L; Zhang J; Zhang X; Ye J; Liang X; Li X; Ke X; Wu Q; Li J; Tao S; Wang X; Rosenfeld P; Heier JS; Kaiser P; Xu X Br J Ophthalmol; 2022 Oct; 106(10):1436-1443. PubMed ID: 34001667 [TBL] [Abstract][Full Text] [Related]
27. Comparison of effectiveness and safety between conbercept and ranibizumab for treatment of neovascular age-related macular degeneration. A retrospective case-controlled non-inferiority multiple center study. Cui J; Sun D; Lu H; Dai R; Xing L; Dong H; Wang L; Wei D; Jiang B; Jiao Y; Jablonski MM; Charles S; Gu W; Chen H Eye (Lond); 2018 Feb; 32(2):391-399. PubMed ID: 28937147 [TBL] [Abstract][Full Text] [Related]
28. Evaluation of ranibizumab and aflibercept for the treatment of diabetic macular edema in daily clinical practice. Plaza-Ramos P; Borque E; García-Layana A PLoS One; 2019; 14(10):e0223793. PubMed ID: 31644594 [TBL] [Abstract][Full Text] [Related]
29. Therapeutic Efficacy of Intravitreal Conbercept Injections with or without Focal Macular Photocoagulation for Diabetic Macular Edema. Mao Y; Wang S; Ji X; Cao K; Hou S; Xiao Y Altern Ther Health Med; 2023 Jul; 29(5):308-313. PubMed ID: 37171942 [TBL] [Abstract][Full Text] [Related]
30. Relation between macular morphology and treatment frequency during twelve months with ranibizumab for diabetic macular edema. Mori Y; Murakami T; Suzuma K; Ishihara K; Yoshitake S; Fujimoto M; Dodo Y; Yoshitake T; Miwa Y; Tsujikawa A PLoS One; 2017; 12(4):e0175809. PubMed ID: 28407012 [TBL] [Abstract][Full Text] [Related]
31. Intravitreal Aflibercept for Patients With Diabetic Macular Edema Refractory to Bevacizumab or Ranibizumab: Analysis of Response to Aflibercept. Chen YY; Chang PY; Wang JK Asia Pac J Ophthalmol (Phila); 2017; 6(3):250-255. PubMed ID: 28436640 [TBL] [Abstract][Full Text] [Related]
32. Functional and Anatomical Outcomes in Patients With Serous Retinal Detachment in Diabetic Macular Edema Treated With Ranibizumab. Giocanti-Aurégan A; Hrarat L; Qu LM; Sarda V; Boubaya M; Levy V; Chaine G; Fajnkuchen F Invest Ophthalmol Vis Sci; 2017 Feb; 58(2):797-800. PubMed ID: 28152140 [TBL] [Abstract][Full Text] [Related]
33. Effect of Vitreomacular Adhesion on Treatment Outcomes in the Ranibizumab for Edema of the Macula in Diabetes (READ-3) Study. Sadiq MA; Soliman MK; Sarwar S; Agarwal A; Hanout M; Demirel S; Rentiya ZS; Khan W; Do DV; Nguyen QD; Sepah YJ; Ophthalmology; 2016 Feb; 123(2):324-329. PubMed ID: 26520169 [TBL] [Abstract][Full Text] [Related]
38. Optical Coherence Tomography Biomarkers in Predicting Treatment Outcomes of Diabetic Macular Edema after Ranibizumab Injections. Chang YC; Huang YT; Hsu AY; Meng PP; Lin CJ; Lai CT; Hsia NY; Chen HS; Tien PT; Lin JM; Chen WL; Tsai YY Medicina (Kaunas); 2023 Mar; 59(3):. PubMed ID: 36984630 [No Abstract] [Full Text] [Related]
39. Treatment outcomes and predicting factors for diabetic macular edema treated with ranibizumab - One-year real-life results in Taiwan. Lai TT; Yang CM; Yang CH; Ho TC; Hsieh YT J Formos Med Assoc; 2019 Jan; 118(1 Pt 1):194-202. PubMed ID: 29609918 [TBL] [Abstract][Full Text] [Related]
40. Effect of Intravitreal Ranibizumab on Intraretinal Hard Exudates in Eyes with Diabetic Macular Edema. Srinivas S; Verma A; Nittala MG; Alagorie AR; Nassisi M; Gasperini J; Sadda SR Am J Ophthalmol; 2020 Mar; 211():183-190. PubMed ID: 31758926 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]